Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 positive |
| Therapy | PLX7486 + unspecified CTLA4 antibody |
| Indication/Tumor Type | colon adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 positive | colon adenocarcinoma | predicted - sensitive | PLX7486 + unspecified CTLA4 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive colon adenocarcinoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy | Full reference... |